Skip to main content

Bio Essence Corp

BIOE
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001723059

No open-market purchases or sales by Bio Essence Corp insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BIOE, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BIOE at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Bio Essence Corp insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2024 (view filing)Oct 28-3021 daysLateYan YinChief Executive OfficerSSale−323.8K$1.40−$454.8K−79.8%82.1K after3 lots
Oct 11, 2024 (view filing)Jun 6, 2023493 daysYan YinChief Executive OfficerPPurchase+5.00M$0.50+$2.50M+55.6%14.0M afterAmended
Oct 10, 2024 (view filing)Sep 25-2715 daysLateYan YinChief Executive OfficerSSale−90.2K$1.13−$102.1K−0.7%13.7M after3 lots
Oct 10, 2024 (view filing)Sep 3010 daysLateYan YinChief Executive OfficerSSale−1.99K$2.35−$4.68K0.0%13.7M after
Oct 10, 2024 (view filing)Jul 2-5100 daysYan YinChief Executive OfficerSSale−224.0K$8.62−$1.93M−1.6%13.8M afterAmended3 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Bio Essence Corp at the end of Q2 2026; share changes are against Q1 2026.

View all: Top 10 13F holders, Q2 2026

No institution reported holding BIOE in 13F filings for Q2 2026.